The EVERY Company, a biotech leader specializing in precision fermentation for high-functionality proteins, announced it closed a $55 million Series D funding round. The round was led by McWin Capital Partners through its McWin Food Tech Fund, with participation from Main Sequence, Bloom8, SOSV, and others. The new capital will expand biomanufacturing capacity and increase its reach in the $270 billion egg market, especially within high-volume bakery segments.
Arturo Elizondo, CEO and Co-Founder of EVERY, expressed enthusiasm about the funding, stating, “This investment allows us to make accessible high-quality products for every community, every city, and every store.” He added that the milestone validates the company’s ambitions and investor confidence.
Building on this momentum, the company plans to scale for mass-market adoption. Starting this month, products featuring EVERY’s proteins will be sold in Walmart across the United States.
EVERY’s proteins are also shelf-stable, with an 18-month shelf life and have a powder format, simplifying supply chain logistics and obviating the need for expensive cold chains – a major advantage for bakeries across the world who rely on refrigerated liquid eggs.
Amidst fluctuating egg prices, EVERY’s fermentation technology offers a stable, cage-free, and shelf-stable egg protein alternative. The technology enables year-round, flexible production, reducing risks from avian flu, salmonella, and supply shocks. Its powdered proteins have an 18-month shelf life, simplifying logistics for bakeries and global food brands.
“EVERY is proving what this technology can do — real products solving real customer problems, at industrial scale, with a clear path to profitability,” said Phil Morle, Partner at Main Sequence. “Their progress shows how biomanufacturing has matured into a resilient, scalable part of the global food supply chain. This is a massive opportunity to build the next generation of food production.”
